查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080180

萊姆病：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

Global Lyme Disease - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國萊姆病市場預計將從2025年的7,000萬美元成長到2035年的1.6億美元。
  • 以下因素推動市場成長：
  • 人們對疾病的認知不斷提高，診斷測試的準確性也日益提高。
  • 持續研發新的抗感染疾病療法和疫苗
  • 未來的成長取決於早期診斷、預防策略和更有效治療方法的進步。

萊姆病概述

萊姆病是由伯氏疏螺旋體引起，透過硬蜱叮咬傳播，是北美和歐洲最常見的蜱傳疾病，其發生率因氣候變遷導致蜱蟲分佈範圍擴大而不斷上升。診斷主要依據臨床症狀及兩步驟血清學檢測。感染早期通常可用強力黴素或阿莫西林治療治愈，但延誤治療可能導致神經系統、心臟和關節的嚴重併發症。同時，萊姆病治療後症候群的症狀仍不甚明了。隨著Pfizer和Valneva聯合研發的六價OspA疫苗候選藥物PF-07307405的問世，預防萊姆病的治療方案取得了顯著進展。2026年3月發表的3期VALOR試驗結果顯示，該疫苗在預防確診個案方面的有效率達73.2%至74.8%。值得注意的是，由於試驗期間的感染人數低於預期，初步分析在技術上未能達到嚴格的主要統計終點。然而，預先設定的次要分析證實了該疫苗具有臨床意義的預防效果。基於這些資料，該公司將於今年稍後向美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）提交上市申請。如果獲得批准，這將是自2002年 LYMErix 疫苗撤市以來首個上市的人類萊姆病疫苗，填補了公共衛生領域的重要空白。

主要亮點

  • 根據預測，德國萊姆病新發病例數將從2025年的56,330 例增加到2035年的57,357 例。
  • 萊姆病是蜱蟲傳播的最常見細菌感染疾病，早期診斷對於預防長期併發症非常重要。
  • 延遲治療或治療不足會導致持續的神經系統、心臟和肌肉骨骼症狀。
  • 對於持續性或難治性病例，診斷和治療方法仍有顯著的未滿足需求，亟需改善。

市場定義：

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

形式和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於MicrosoftExcel）
  • 流行病學資料（MS Excel，互動式工具）
  • 高層洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東

提及公司

  • Pfizer
  • ModernaTX, Inc.
  • Tarsus Pharmaceuticals, Inc.
  • Biocodex

目錄

第1章 主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者群體
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 依藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法 - 概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期管道

第6章 未滿足的需求與TPP分析

  • 主要未滿足需求及新興療法的未來成就
  • TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

簡介目錄

Global Lyme Disease Market Outlook

Thelansis's "Global Lyme Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lyme Disease treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Lyme Disease Overview

Lyme disease, caused by Borrelia burgdorferi and transmitted through Ixodes tick bites, is the most prevalent vector-borne illness across North America and Europe, with its incidence climbing due to climate-driven tick range expansion. Diagnosis relies on clinical presentation and two-tier serology. Early-stage infection is typically curable with doxycycline or amoxicillin, but delayed treatment can progress to debilitating neurological, cardiac, and arthritic complications, while post-treatment Lyme disease syndrome remains poorly understood. Prophylactic options have advanced significantly with Pfizer and Valneva's investigational 6-valent OspA-based vaccine candidate PF-07307405. In the Phase 3 VALOR trial results announced in March 2026, the vaccine demonstrated 73.2 to 74.8 percent efficacy in preventing confirmed cases. Crucially, due to a lower-than-expected number of infections during the study period, the trial technically missed its strict primary statistical endpoint in the first analysis, though a secondary pre-specified analysis confirmed clinically meaningful protection. Based on these data, regulatory submissions to the FDA and EMA are moving forward this year. If approved, it will become the first human Lyme disease vaccine available since the withdrawal of LYMErix in 2002, filling a massive public health gap.

Key Highlights

  • In Germany, incident Lyme disease cases are projected to increase from 56,330 in 2025 to 57,357 by 2035.
  • Lyme disease is the most common tick-borne bacterial infection, with early diagnosis being critical to prevent long-term complications.
  • Delayed or inadequate treatment may lead to persistent neurological, cardiac, and musculoskeletal manifestations.
  • Significant unmet need remains for improved diagnostics and therapies for persistent or difficult-to-treat disease.

Market Overview

  • The France Lyme disease market is projected to grow from $70M in 2025 to $160M by 2035.
  • Market growth is driven by:
  • Increasing disease awareness and improved diagnostic testing
  • Ongoing development of novel anti-infective therapies and vaccines
  • Future growth will depend on advancements in early diagnosis, preventive strategies, and more effective treatment options.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle Ea

Companies Mentioned

  • Pfizer
  • ModernaTX, Inc.
  • Tarsus Pharmaceuticals, Inc.
  • Biocodex

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)